Understanding IgA Nephropathy and the Importance of Treatment
IgA nephropathy (IgAN) leads to kidney damage due to the deposition of immunoglobulin A (IgA) in the kidney’s mesangium, resulting in inflammation and scarring. Symptoms can vary widely, from minor hematuria to significant proteinuria and chronic kidney disease (CKD). Without effective treatment, many patients with ongoing proteinuria or declining estimated glomerular filtration rate (eGFR) may face kidney failure; nearly one-third of patients can progress to end-stage kidney disease within 10 to 20 years, highlighting the need for timely intervention to preserve kidney function and lower cardiovascular risks.
Essential Treatment Strategies for IgA Nephropathy
The initial step in managing IgAN focuses on comprehensive supportive care to minimize proteinuria and cardiovascular risks. This management typically involves strict blood pressure control using medications like ACE inhibitors or angiotensin receptor blockers (ARBs), along with dietary sodium reduction, cholesterol management, and, for some patients, sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors have demonstrated effectiveness in reducing kidney-related outcomes in patients with proteinuric CKD, making them a core component of supportive care for those with IgAN.
For patients exhibiting more concerning features, such as persistent proteinuria despite ideal supportive care or declining eGFR, targeted therapies may be warranted. Traditional systemic corticosteroids and immunosuppressants have potential side effects and variable efficacy. However, recent advancements include targeted therapies that directly address IgAN’s underlying mechanisms and may offer improved outcomes with reduced toxicity.
Emerging Therapies: New Frontiers in Treatment
One promising option is TARPEYO, a targeted-release budesonide that acts specifically at the ileal Peyer’s patches to decrease the production of abnormal IgA1 while minimizing systemic steroid exposure. Approved for adults with primary IgAN at high risk of rapid progression, TARPEYO presents a novel approach to treatment focusing on mucosal immunity rather than systemic immunosuppression.
Another innovative treatment, Sparsentan (FILSPARI), combines inhibition of both endothelin type A and angiotensin receptors, showing superior proteinuria reduction compared to irbesartan in clinical trials. This option, now approved for selected IgAN patients, adds another layer to the treatment arsenal against proteinuria.
Complement-pathway inhibitors, such as Iptacopan, mark significant progress as well. As an oral Factor B inhibitor, it has demonstrated beneficial effects on proteinuria and kidney function in trials, receiving accelerated approval in some areas. Other therapies targeting the complement system are currently under investigation, reflecting a growing focus on this pathway in IgAN management.
Research also continues into various novel agents aiming at B-cells, inflammation reduction, and unique small molecules. Several of these treatments are nearing the completion of phase 2-3 studies, with some showing promising intermediate results in proteinuria reduction. Ongoing studies of immune-modulating monoclonal antibodies like sibeprenlimab are also underway, offering further options for consideration.
Complementary Lifestyle Modifications for Kidney Health
Effectiveness of therapies can be enhanced significantly through lifestyle adjustments that lower stress on the kidneys and cardiovascular system. Key recommendations for patients with IgAN include maintaining targeted blood pressure levels, adhering to a low-sodium diet, managing weight, engaging in regular exercise per medical guidance, and addressing any dyslipidemia and diabetes as recommended. Additionally, stopping smoking and staying current with vaccinations is critical, particularly for those on immunomodulatory treatments. Regular check-ups to monitor urine protein, serum creatinine/eGFR, and blood pressure can support therapy adjustments. Practice guidelines underscore the necessity of a solid supportive care foundation, ideally in conjunction with any specific disease treatments.
The Future of Managing IgA Nephropathy
The field of IgAN management is rapidly evolving with new targeted therapies now available, offering previously unattainable treatment options. The integration of mucosal-targeted therapies, dual receptor blockers, and oral complement inhibitors, alongside established care like SGLT2 inhibitors, suggests a more personalized approach to treatment. As ongoing studies continue to assess long-term outcomes, the medical community aims to refine treatment protocols to achieve optimal care tailored to each patient’s unique situation, including proteinuria levels and kidney function.
For patients, establishing a robust dialogue with their nephrology team is vital. Understanding whether they are receiving comprehensive supportive care, including effective use of RAS blockers and potential consideration for SGLT2 inhibitors, is important. Discussing the potential criteria for new therapies or clinical trials may open additional pathways for managing IgAN effectively, with the goal of slowing or delaying the progression to kidney failure through individualized evaluations of risks and benefits.
The content is provided by Sierra Knightley, Lifelong Health Tips
